Hospital Universitario Virgen de la Victoria
Hospital
Location:
Málaga,
Spain (ES)
ISNI: 0000000097882492
ROR: https://ror.org/05xxs2z38
Cardiovascular fingolimod effects on rapid baroreceptor unloading are counterbalanced by baroreflex resetting (2021)
Hilz MJ, Roy S, de Rojas Leal C, Liu M, Canavese F, Winder K, Hoesl KM, et al.
Journal article
A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease (2020)
González-Serna D, Ochoa E, López-Isac E, Julià A, Degenhardt F, Ortego-Centeno N, Radstake TR, et al.
Journal article
Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2,-3, and-7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptore-positive, HER2-negative (HR+/HER2L) advanced breast cancer (ABC) (2020)
Fasching P, Bardia A, Nusch A, Jerusalem G, Chan A, El Saghir N, Alba E, et al.
Conference contribution
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways (2019)
López-Isac E, Acosta-Herrera M, Kerick M, Assassi S, Satpathy AT, Granja J, Mumbach MR, et al.
Journal article
THE NOX1/4 INHIBITOR GKT831 ACHIEVES CLINICALLY MEANINGFUL REDUCTIONS IN LIVER STIFFNESS, ATTENUATES CHOLESTASIS, AND IMPROVES QUALITY OF LIFE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (2019)
Huang JC, Invernizzi P, Dalekos GN, Nevens F, Van Vlierberghe H, Zigmond E, Andrade RJ, et al.
Conference contribution
Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial (2019)
Dalekos G, Invernizzi P, Nevens F, Hans VV, Zigmond E, Andrade RJ, Ben Ari Z, et al.
Conference contribution